TREATMENT EFFECTS OF ALIROCUMAB AS AN ADD-ON TO MAXIMALLY TOLERATED DOSE OF STATIN IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AND/OR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE

Robert J. Weiss,Seth Baum,Dirk Blom,Jean Bergeron,Gisle Langslet,Santosh K. Sanganalmath, Julia Yang,Jonas Mandel,Prediman Shah

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY（2017）

引用 0|浏览7

暂无评分

摘要

Background: Patients (Pts) with atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial hypercholesterolemia (HeFH) are at high cardiovascular risk. Despite maximally tolerated dose (MTD) of statin, many have high levels of low-density lipoprotein cholesterol (LDL-C). We present the

查看译文

关键词

statin,heterozygous familial hypercholesterolemia,familial hypercholesterolemia,atherosclerotic cardiovascular disease,alirocumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要